Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

763 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Brown JE, Royle KL, Gregory W, Ralph C, Maraveyas A, Din O, Eisen T, Nathan P, Powles T, Griffiths R, Jones R, Vasudev N, Wheater M, Hamid A, Waddell T, McMenemin R, Patel P, Larkin J, Faust G, Martin A, Swain J, Bestall J, McCabe C, Meads D, Goh V, Min Wah T, Brown J, Hewison J, Selby P, Collinson F; STAR Investigators. Brown JE, et al. Among authors: brown j. Lancet Oncol. 2023 Mar;24(3):213-227. doi: 10.1016/S1470-2045(22)00793-8. Epub 2023 Feb 13. Lancet Oncol. 2023. PMID: 36796394 Free article. Clinical Trial.
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).
Vasudev NS, Ainsworth G, Brown S, Pickering L, Waddell T, Fife K, Griffiths R, Sharma A, Katona E, Howard H, Velikova G, Maraveyas A, Brown J, Pezaro C, Tuthill M, Boleti E, Bahl A, Szabados B, Banks RE, Brown J, Venugopal B, Patel P, Jain A, Symeonides SN, Nathan P, Collinson FJ, Powles T. Vasudev NS, et al. J Clin Oncol. 2024 Jan 20;42(3):312-323. doi: 10.1200/JCO.23.00236. Epub 2023 Nov 6. J Clin Oncol. 2024. PMID: 37931206 Free PMC article. Clinical Trial.
Major Publications in the Critical Care Pharmacotherapy Literature: 2023.
Murray B, Athale J, Balk RA, Behal ML, Brown JE, Chanas T, Dumitru R, Gifford DC, Hohlfelder B, Jones HM, Makic MBF, Rausen MS, Sacco AJ, Sines BJ, Gurnani PK. Murray B, et al. Among authors: brown je. Crit Care Explor. 2024 Oct 3;6(10):e1162. doi: 10.1097/CCE.0000000000001162. eCollection 2024 Oct 1. Crit Care Explor. 2024. PMID: 39360775 Free PMC article. Review.
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy.
Al-Janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, de Bono J, Nunns H, Bailey C, Junker-Jensen A, Muthana M, Phillips WA, Pearson HB, Taplin ME, Brown JE, Lewis CE. Al-Janabi H, et al. Among authors: brown je. J Immunother Cancer. 2024 Jul 25;12(7):e009368. doi: 10.1136/jitc-2024-009368. J Immunother Cancer. 2024. PMID: 39060021 Free PMC article.
763 results